Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boston Pharmaceuticals

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

6 comunicati stampa

Guarda tutti i comunicati
14/05/2025
Mercato azionario
Mercato del lavoro
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
Boston Pharmaceuticals to Present the Effect of Efimosfermin Alfa on Collagen Biomarkers in Patients with F2 and F3 MASH at EASL Congress 2025
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0
23/04/2025
Eventi
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week® 2025
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0
15/11/2024
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Fiere
Eventi
Industria
Web e Social Network
Telefonia e Varie
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting®
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0
16/10/2024
Eventi
Fiere
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Boston Pharmaceuticals to Present Phase 2 Biopsy Results for Long-Acting, Once-Monthly FGF21 Analogue Efimosfermin Alfa (BOS-580) in F2 and F3 MASH in Late-Breaking Oral Presentation at AASLD, The Liver Meeting® 2024
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0
05/06/2024
Fiere
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Boston Pharmaceuticals Presents Data at EASL Congress 2024 Showing Treatment With Long-acting FGF21 Analogue, BOS-580, Improved Lipid Profiles in Patients with Phenotypic MASH
Fonte
Boston Pharmaceuticals
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0